Sara M. Tolaney, MD, MPH
In a video interview, Sara M. Tolaney, MD, MPH, division of breast oncology chief and associate director at Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, discussed:
- how treatments for HER2-positive breast cancer have evolved;
- what it means for a patient to be diagnosed with HER2-low breast cancer and the challenges of treatment;
- the emergence of therapies that are specially tailored to patients with HER2-low breast cancer markers;
- the short- and long-term side effects oncologists should consider when treating patients with HER2-positive breast cancer; and
- barriers to access in breast cancer diagnosis and treatment, and how they can be addressed.
Disclosures: Tolaney reports serving on advisory boards, consulting for, receiving institutional research funds from and/or receving honorarium from 4D Pharm, ARC Therapeutics, Athenex, AstraZeneca, BeyondSpring Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb, Certara, Chugai Pharmaceuticals, Cyclacel, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, Ellipses Pharma, Exelixis, Genentech/Roche, Gilead, Infinity Therapeutics, Merck, Menari/Stemline, Mersana Therapeutics, Myovant, Nanostring, Nektar, Novartis, Odonate, OncoSec Medical Incorporated, OncXerna, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Umoja Biopharma, Zentalis and Zymeworks.
Read more about
Click Here to Manage Email Alerts